TNF Inhibitor denied as duplicate or overlapping therapy by Florida Blue?

Florida Blue uses Prime Therapeutics or CVS Caremark depending on plan line. Step therapy through preferred biosimilar.

FL Statute 627.42393 limits step therapy when prior failure documented. Demand peer-to-peer review. Cite continuity-of-care for stable patients.

## Why Florida Blue Denies TNF Inhibitors as Duplicate Therapy

A duplicate-therapy denial from Florida Blue means the plan's review system identified that you are already approved for or actively receiving another medication it considers therapeutically equivalent or overlapping with the requested TNF inhibitor. This most commonly occurs when a patient is being transitioned between biologic agents, when a biosimilar is approved alongside a reference product, or when a second biologic from a different class is being added to an existing biologic. Florida Blue's policy is designed to avoid what it considers redundant coverage, but the criteria for what counts as "duplicate" are defined in its coverage policy — and that definition may not match your clinical reality.

## Why This Denial Is Appealable

Duplicate-therapy determinations are inherently clinical judgments, and they are appealable when your prescriber can document that the two agents are not actually interchangeable or redundant in your case. Different TNF inhibitors have different molecular structures, administration routes, and clinical track records for specific conditions. A switch from one biologic to another, or the addition of a second agent for a distinct indication, is not duplication — it is individualized treatment. Florida Blue must consider your prescriber's clinical rationale.

## Federal Appeal Rights

• Internal appeal: File under ERISA §503 (employer-sponsored plans) or Florida's insurance code (individual/fully-insured plans). Florida Blue must provide a full-and-fair review by a reviewer not involved in the original determination.
• External review (ACA §2719): After exhausting internal appeals, you may request independent external review, generally within four months of the final internal denial.
• Expedited review: If clinical urgency exists — such as a disease flare during a medication transition — request expedited review for a decision within 72 hours.

## Documentation to Gather

1. Explanation of the clinical distinction: A prescriber letter explaining why the requested TNF inhibitor is not a duplicate of the current or prior therapy — including differences in mechanism, indication subtype, administration route, or patient-specific factors. 2. Transition rationale: If you are switching biologics, document why the prior agent is being discontinued (inadequate response, adverse effect, change in disease activity, formulary change). 3. Distinct indication documentation: If the TNF inhibitor is being used for a different diagnosis than the other biologic, document both conditions clearly in chart notes. 4. Florida Blue coverage policy: Obtain the specific duplicate-therapy policy to understand exactly how Florida Blue defines duplication and respond to each criterion. 5. Current medication list with prescriber rationale: A full medication list with clinical justification for each agent shows that the treatment plan is intentional, not duplicative.

## Criteria-Mapping Structure

| Florida Blue Duplicate-Therapy Criterion | Your Rebuttal Evidence | |---|---| | Both agents treat the same condition | [Explanation of distinct indications or clinical roles] | | Agents are therapeutically interchangeable | [Prescriber rationale for non-interchangeability] | | Prior agent still active/approved | [Discontinuation date and reason, or distinction in use] |

The appeal succeeds when the prescriber's letter makes clear — in clinical terms — why having both agents (or transitioning to the new one) is the appropriate course of treatment for this specific patient.